Jump to content

Tucidinostat: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→top: {{As of|April 2015}} it is only approved in China.<ref
drugbox
Tag: nowiki added
Line 1: Line 1:
{{Infobox drug
⚫
'''Chidamide''' ('''Epidaza''') is an [[HDAC inhibitor]] developed wholly in China, that shows potential in treating [[pancreatic cancer]].<ref>{{cite journal|last1=Qiao|first1=Z|title=Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.|journal=Biochem Biophys Res Commun.|date=2013-04-26|volume=434|issue=1|pages=95-101|doi=10.1016/j.bbrc.2013.03.059|pmid=23541946}}</ref><ref>{{cite journal|last1=Guha|first1=Malini|title=HDAC inhibitors still need a home run, despite recent approval|journal=Nature Reviews Drug Discovery|date=2015-04-01|volume=14|pages=225–226|doi=10.1038/nrd4583|url=http://www.nature.com/nrd/journal/v14/n4/full/nrd4583.html}}</ref><ref>{{cite news|last1=Wang|first1=Shirley S.|title=A New Cancer Drug, Made in China|url=http://www.wsj.com/articles/a-new-cancer-drug-made-in-china-1428004715|accessdate=13 April 2015|agency=The Wall Street Journal|date=2015-04-02}}</ref>
| drug_name =
| IUPAC_name = ''N''-​(2-​Amino-​5-​fluorophenyl)-​4-​<nowiki>[[[</nowiki>1-​oxo-​3-​(3-​pyridinyl)-​2-​propen-​1-​yl]amino]methyl]-​benzamide
| image = Chidamide.svg
| alt =
| caption =

<!-- Clinical data -->
| tradename = Epidaza
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_category=
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_NZ = <!--Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status =
| routes_of_administration =

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| onset =
| elimination_half-life =
| excretion =

<!-- Identifiers -->
| CAS_number = 743420-02-2
| ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix =
| PubChem =
| DrugBank =

<!-- Chemical data -->
| chemical_formula = C<sub>22</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>
| molecular_weight = 390.4 g/mol
| smiles = NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1
}}

⚫
'''Chidamide''' ('''Epidaza''') is an [[HDAC inhibitor]] developed wholly in China that shows potential in treating [[pancreatic cancer]].<ref>{{cite journal|last1=Qiao|first1=Z|title=Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.|journal=Biochem Biophys Res Commun.|date=2013-04-26|volume=434|issue=1|pages=95-101|doi=10.1016/j.bbrc.2013.03.059|pmid=23541946}}</ref><ref>{{cite journal|last1=Guha|first1=Malini|title=HDAC inhibitors still need a home run, despite recent approval|journal=Nature Reviews Drug Discovery|date=2015-04-01|volume=14|pages=225–226|doi=10.1038/nrd4583|url=http://www.nature.com/nrd/journal/v14/n4/full/nrd4583.html}}</ref><ref>{{cite news|last1=Wang|first1=Shirley S.|title=A New Cancer Drug, Made in China|url=http://www.wsj.com/articles/a-new-cancer-drug-made-in-china-1428004715|accessdate=13 April 2015|agency=The Wall Street Journal|date=2015-04-02}}</ref>


{{As of|April 2015}} it is only approved in China.<ref>{{cite web |url=http://seekingalpha.com/article/3055626-chinas-first-homegrown-pharma |title=China's First Homegrown Pharma. |date=April 2015}}</ref>
{{As of|April 2015}} it is only approved in China.<ref>{{cite web |url=http://seekingalpha.com/article/3055626-chinas-first-homegrown-pharma |title=China's First Homegrown Pharma. |date=April 2015}}</ref>

Revision as of 20:04, 17 April 2015

Tucidinostat
Clinical data
Trade namesEpidaza
Identifiers
  • N-​(2-​Amino-​5-​fluorophenyl)-​4-​[[[1-​oxo-​3-​(3-​pyridinyl)-​2-​propen-​1-​yl]amino]methyl]-​benzamide
CAS Number
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H19FN4O2
Molar mass390.4 g/mol
3D model (JSmol)
  • NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1

Chidamide (Epidaza) is an HDAC inhibitor developed wholly in China that shows potential in treating pancreatic cancer.[1][2][3]

As of April 2015 it is only approved in China.[4]

References

  1. ^ Qiao, Z (2013-04-26). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochem Biophys Res Commun. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
  2. ^ Guha, Malini (2015-04-01). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews Drug Discovery. 14: 225–226. doi:10.1038/nrd4583.
  3. ^ Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.
  4. ^ "China's First Homegrown Pharma". April 2015.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tucidinostat&oldid=656944892"